Caring for people with learning disabilities and dementia: pharmacotherapeutic considerations

Lynette Harper*, Sarah Mackay

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

People with learning disabilities, particularly those with Down’s syndrome, are at increased risk of developing dementia, often at a younger age than the general population. Although there is no cure for dementia, treatment can include dementia medicines that aim to alleviate the associated symptoms and delay progression of the disease. The dementia medicine selected depends on the type and stage of the condition, contraindications and potential drug interactions with those prescribed for comorbid health conditions. This article provides an overview of dementia in people with learning disabilities and explores the use of dementia medicines in this population, including the implications of comorbidities and polypharmacy in terms of dose titration and risk of side effects. The authors also discuss new and emerging dementia medicines
Original languageEnglish
Number of pages8
JournalLearning Disability Practice
Volume28
Issue number4
Early online date8 May 2025
DOIs
Publication statusPublished - 7 Aug 2025

Keywords

  • adverse reactions
  • Alzheimer’s disease
  • clinical
  • comorbidity
  • dementia
  • Down’s syndrome
  • learning disability
  • medicines
  • medicines review
  • neurology
  • nursing care
  • pharmacology
  • professional

Fingerprint

Dive into the research topics of 'Caring for people with learning disabilities and dementia: pharmacotherapeutic considerations'. Together they form a unique fingerprint.

Cite this